Autres langues Leo Acquisitions Corp Toronto S.E.

Actions

LEQ.H

CA5263612098

Cours en clôture Toronto S.E. Autres places de cotation 00:00:00 24/11/2023			Varia. 5j.	Varia. 1 janv.
0,01 ^CAD	+33,33%		-.--%	-.--%

2021	PsyBio Therapeutics dépose auprès de l'USPTO un brevet sur de nouvelles compositions psychédéliques et des méthodes de traitement	MT
2021	PsyBio renforce son équipe de direction en nommant le Dr Michael Spigarelli au poste de directeur médical.	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

PsyBio Therapeutics : Reports Second Quarter 2021 Financial Results and Provides Corporate Update on Intellectual Property and Clinical Development Milestones	30/08/21
PsyBio Therapeutics : Files Patent Application with USPTO for Production Methods of Methylated Trypatamines and Associated Analogs	16/08/21
PsyBio Therapeutics Files Patent Application with USPTO for Production Methods of Methylated Trypatamines and Associated Analogs	16/08/21
PsyBio Therapeutics : Adds NMDA Receptor Antagonists and Associated Analogues into its Intellectual Property Portfolio	04/08/21
PsyBio Therapeutics : CEO and CMO to Participate in Fireside Chat at LifeSci Partners Summer Symposium	20/07/21
PsyBio Therapeutics : Announces Uplisting to OTCQB Venture Market	14/07/21
PsyBio Therapeutics : Files Novel Psychedelic Compositions and Methods of Treatment Patent With USPTO	13/07/21
PsyBio Therapeutics : Augments Intellectual Property Portfolio with Filing of Next Novel Psychedelic Compositions and Methods of Treatment Patent	13/07/21
PsyBio Therapeutics : Announces TSXV Approval of Share Buyback Program	28/06/21
Psybio Therapeutics Corp. Initiates European Manufacturing of Proprietary Biosynthetic Psychedelic Compounds	22/06/21
PsyBio Therapeutics : Initiates European Manufacturing of Proprietary Biosynthetic Psychedelic Compounds including Psilocybin with France-based Biose Industrie	22/06/21
PsyBio Therapeutics Corp. Announces Executive Changes	01/06/21
PsyBio Therapeutics Corp.'s Board intends to launch an Equity Buyback.	01/06/21
IRW-News: PsyBio Therapeutics Corp.: PsyBio Therapeutics beruft erfahrene pharmazeutische Führungskraft Bob Oliver in sein Board of Directors	21/04/21
PsyBio Therapeutics : Appoints Pharmaceutical Veteran Bob Oliver to its Board of Directors	21/04/21
PsyBio Therapeutics : Retains KCSA Strategic Communications for Investor Relations Services	09/04/21
PsyBio Therapeutics : Strengthens Leadership Team with Appointment of Dr. Michael Spigarelli as Chief Medical Officer	05/04/21
PsyBio Therapeutics : Strengthens its Leadership Team with Appointment of Dr. Michael Spigarelli as Chief Medical Officer	05/04/21
IRW-News: PsyBio Therapeutics Corp.: PsyBio Therapeutics beginnt mit Prozessentwicklung von eigenem biosynthetischem Norbaeocystin	23/03/21
PsyBio Therapeutics Announces Retention of Market Maker	04/03/21

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Leo Acquisitions Corp Toronto S.E.

Actions

LEQ.H

CA5263612098

Autres langues

Filtres